Boehringer Ingelheim recently announced that Pradaxa reversal agent, Praxbind (idarucizumab), is now stocked in over 2,200 hospitals throughout the United States.

Praxbind was released in late 2015, when Boehringer Ingelheim had developed a Pradaxa reversal agent five years after its initial release.

During these five years after the release of Pradaxa and before the release of Praxabind, thousands of patients have reported internal bleeding injuries allegedly caused by the medication.

Pradaxa was approved by the FDA in 2010, and was the first anticoagulant to be released into the market since warfarin six decades ago.

Pradaxa is usually prescribed to prevent stroke in patients at high risk for other high blood clot attacks. Even though this drug is effective in preventing blood clot formation, it also inhibits the body’s ability to recover from internal bleeding injuries.

Until recently, warfarin was the only anticoagulant with a widely available bleeding antidote. Pradaxa and other new generation anticoagulants were advertised to be more convenient and superior to warfarin, as they carried the same benefits and are only prescribed in a standardized dose.

Even though warfarin patients were required to frequently see their doctors for dose adjustments, all they had to do was implement vitamin K to stop the bleeding in the event of an uncontrolled bleeding event.

At this point in time, Pradaxa has been allegedly linked to at least 260 deaths worldwide due to uncontrolled bleeding.

Overview of Pradaxa Reversal Agent

Boehringer Ingelheim has also launched a new locator on PRAXBIND.com, which helps healthcare providers and Pradaxa patients to find the nearest hospital that stocks the Pradaxa reversal agent.

The German manufacturing company is proud of successfully producing Praxbind, and is even more thrilled to announce its now wide range availability.

The FDA had approved Praxbind for Pradaxa patients suffering from internal bleeding injuries, which had shown promising results during preclinical trials.

In fact, the Pradaxa reversal agent had been granted the Accelerated Approval Pathway after receiving positive results from its RE-VERSE AD trial.

The Pradaxa reversal agent had almost immediate effect of the Pradaxa patients, who were otherwise healthy aside from their internal bleeding injuries.

While there are several side effects to be concerned with Praxbind, such as thrombotic events, the most commonly reported complication has been headache, with medical experts confident in the ability of the Pradaxa reversal agent.

Considering the serious problems associated with Pradaxa internal bleeding, the increasing availability of this product will greatly help the patient’s chances of survival.

Even though Boehringer Ingelheim has introduced this new remedy, it does not help the Pradaxa patients who have already suffered internal bleeding.

Plaintiffs who took legal action against the manufacturer claim that Boehringer Ingelheim had allegedly known the risk of Pradaxa internal bleeding, but had omitted this information from the drug’s warning label.

Pradaxa patients who have experienced internal bleeding may be eligible to file legal action, and should contact a specialized lawyer.